FDA Reviewer Supports Cardiokine Low-Sodium Drug for One of Two Proposed Indications
Cardiokine’s lixivaptan should be approved to treat low sodium levels associated with syndrome of inappropriate antidiuretic hormone (SIADH), an FDA reviewer says.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.